Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite presented as a subcutaneous formulation for injection use. It is employed in the management of certain cancers, autoimmune disorders and specific gestational conditions, targeting rapidly dividing cells and modulating immune responses.

GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable logistics for critical therapies.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation and plaque formation. - Acute lymphoblastic leukemia: interferes with malignant cell DNA synthesis. - Non‑Hodgkin lymphoma: impedes growth of lymphoma cells. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Mouth sores or ulceration. - Elevated liver enzymes. - Low blood cell counts. - Temporary hair thinning.

Serious or Rare Side Effects: - Severe infection due to bone‑marrow suppression. - Pulmonary toxicity (interstitial pneumonitis). - Significant hepatotoxicity or liver fibrosis. - Acute renal failure. - Life‑threatening skin reactions (e.g., Stevens‑Johnson syndrome). - Marked bone‑marrow failure leading to pancytopenia.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters. - Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: check transaminases and bilirubin periodically. - Evaluate renal function: adjust dosing if creatinine clearance is reduced. - Avoid in pregnancy: methotrexate is teratogenic (Category X). - Use effective contraception: both male and female patients of reproductive potential must use reliable birth control. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Methotrexate interacts with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins and other β‑lactam antibiotics: may enhance myelosuppression. - Sulfonamide antibiotics: can raise plasma methotrexate levels.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may reduce renal clearance of methotrexate. - Folic acid or folinic acid supplements: can diminish therapeutic effect. - Live vaccines: increased risk of infection due to immunosuppression.